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Background and purpose: In 2011, ﬁngolimod was approved in Switzerland
for the treatment of relapsing-remitting multiple sclerosis (RRMS). The aim of
the present study was to assess the eﬀectiveness and retention of ﬁngolimod in
a real-life Swiss setting, in which patients can receive ﬁngolimod as both ﬁrst-
and second-line treatment for RRMS.
Methods: This cross-sectional, observational study with retrospective data
collection was performed at 19 sites that comprised both hospitals and office-
based physicians across Switzerland. Sites were asked to document eligible
patients in consecutive chronological order to avoid selection bias. Demo-
graphic and clinical data from 274 consenting adult patients with RRMS who
had received treatment with ﬁngolimod were analyzed.
Results: Mean treatment duration with ﬁngolimod was 32 months. Under ﬁn-
golimod, 77.7% of patients remained free from relapses and 90.3% did not
experience disability progression. The proportion of patients who were free
from any clinical disease activity, i.e. without relapses and disability progres-
sion, was 72.1%. A total of 28.5% of patients had been RRMS treatment-
na€ıve prior to ﬁngolimod therapy. High long-term treatment retention rates
ranging between 95.7% at 24 months and 87.8% at 36 months were observed.
Conclusion: In this Swiss cohort of na€ıve and pre-treated subjects with
RRMS, the majority of patients under ﬁngolimod treatment showed freedom
from relapses and disability progression. In addition, treatment retention rate
over 2 and 3 years was high, irrespective of previous treatment.
Introduction
Long-term treatment objectives in relapsing-remitting
multiple sclerosis (RRMS) have come increasingly
into focus, including prevention of relapses, disability
progression, accumulation of brain lesions and brain
atrophy [1]. Therefore, the long-term aim of RRMS
therapy is to suppress disease activity.
It is now well accepted in clinical practice that
eﬀective disease-modifying therapy (DMT) should be
initiated as early as possible to better achieve these
long-term therapy goals [1,2].
Long-term treatment retention and adherence to
therapy are also crucial for optimal outcomes [3].
Therefore, careful and individualized selection of a
highly eﬀective and tolerable DMT regimen will
increase treatment adherence, which is vital for long-
term treatment success.
Fingolimod (Gilenya, Novartis Pharma AG, Basel,
Switzerland) is the ﬁrst approved oral DMT
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worldwide [4–6]. In Switzerland, as opposed to the
European Union and some other countries where only
a second-line label has been granted, ﬁngolimod was
also approved in 2011 for RRMS as a ﬁrst-line treat-
ment. In the three pivotal clinical trials, ﬁngolimod
was efficacious in reducing relapse rate, progression of
disability, accumulation of new brain lesions as well
as progression of brain atrophy compared with pla-
cebo or intramuscular interferon beta-1a [4,5,7].
Several observational studies have been published
that investigated the eﬀectiveness of ﬁngolimod in a
more heterogeneous population of patients as com-
pared with those included in clinical trials [8]. These
real-world data conﬁrmed ﬁndings from clinical trials
in terms of preventing relapses and disability progres-
sion, and highlight that ﬁngolimod retention over
longer periods of time is generally high, particularly if
compared with injectable ﬁrst-line therapies [9,10].
The aim of the present study was to provide further
data on ﬁngolimod use under real-life conditions, par-
ticularly for na€ıve and pre-treated patients with
RRMS in Switzerland.
Methods
Patients and study design
This observational, multi-center, cross-sectional study
with retrospective secondary data collection was con-
ducted at 19 clinics and office-based neurologists spe-
cializing in multiple sclerosis across Switzerland
between August 2015 and January 2016.
Adult patients with RRMS (≥18 years of age) were
eligible if they had received uninterrupted (i.e. no inter-
ruptions lasting longer than 4 weeks) treatment with
commercially available ﬁngolimod for at least
6 months. If these criteria were fulﬁlled, patients for
whom ﬁngolimod had already been discontinued at the
time of data documentation were also included in the
study. As per the observational plan, patients were
included in a chronological and consecutive manner (as
of ﬁngolimod marketing authorization in Switzerland
in January 2011).
The study was approved by the respective local
ethics committees and written informed consent was
obtained from patients prior to the start of the
study.
The primary objective of the study was to assess the
long-term eﬀectiveness of ﬁngolimod in patients with
RRMS in terms of freedom from relapses. Secondary
objectives included the collection of data on freedom
from disability progression and treatment retention,
deﬁned as the proportion of patients who, at a given
time, continued to receive ﬁngolimod.
Data from 275 consecutive patients were collected
and data from 274 patients were analyzed. One
patient who was less than 18 years of age at the time
of data collection (17 years old, oﬀ-label use) was
excluded from the analysis.
Clinical and radiological data from the patient’s last
available assessment prior to initiating ﬁngolimod
treatment and data from the most recent assessment
under ﬁngolimod therapy were entered into paper-
based case report forms. The data collected covered
periods before and during ﬁngolimod treatment, and
included demography, treatment history and number
of relapses under ﬁngolimod and in the 24 months
before starting ﬁngolimod. Relapses were deﬁned
according to the McDonald criteria [11]. Disability
progression between two assessments was deﬁned as
an increase of ≥1 points in the Expanded Disability
Status Score (EDSS) [12].
Statistical methods
Quantitative data were analyzed by descriptive statisti-
cal parameters. Qualitative and ordinal data were
described by absolute and relative frequency distribu-
tions, and percentages were based on valid data. The
annualized relapse rate was calculated as number of
relapses divided by the exact (decimal) number of
years on ﬁngolimod treatment. Analyses were per-
formed for the total sample and stratiﬁed according
to the duration of treatment with ﬁngolimod and pre-
treatment history. Wilcoxon tests for paired samples
were used for statistical comparison of values before
and under ﬁngolimod treatment. All analyses were
performed using the SAS package (version 9.2; SAS
Institute Inc., Cary, NC, USA).
Results
Patient characteristics
The patient characteristics are summarized in Table 1.
Fingolimod was used as a ﬁrst-line therapy in 78
patients (28.5%). Patients who were switched from
another DMT to ﬁngolimod had previously most fre-
quently received one of the interferons (Fig. 1).
Effectiveness
The median (interquartile range) ﬁngolimod treatment
duration at the time of documentation was 31.1 (23.7–
42.1) months (mean  SD, 32.0  11.8 months).
Overall, 213 (77.7%) patients remained free from
relapses under ﬁngolimod treatment. Over the same
period, this ﬁgure was 74.4% (58 of 78 patients) and
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79.1% (155 of 196 patients) in the groups of treat-
ment-na€ıve and pre-treated patients, respectively
(Fig. 2).
The relapse freedom rate was 79.3% in patients
who had last received injectable DMTs (interferons/
glatiramer acetate, n = 150) and 78.6% in patients
who had been switched to ﬁngolimod after receiving
natalizumab (n = 42) (Fig. 2). The mean (SD)
annual relapse rate under ﬁngolimod was 0.12
(0.28). The mean annual relapse rate also remained
similarly low (0.12  0.28) after excluding from the
analysis those 12 patients who were treated with ﬁn-
golimod for less than 12 months. A total of 93% of
patients who were relapse-free before ﬁngolimod initi-
ation (n = 78) did not show any further relapses under
ﬁngolimod treatment. Similarly, 78.8%, 64.6% and
50.0% of patients who had had one (n = 89), two
(n = 42) or three or more (n = 18) relapses prior to
initiation of ﬁngolimod, respectively, were free from
relapses under ﬁngolimod treatment.
When stratifying patients according to the duration
of ﬁngolimod treatment, the proportion of those free
from relapses was 91.7%, 82.5%, 76.9% and 74.1%
during year 1, 2, 3 and over 3 years of therapy
(Table 2).
A total of 243 (90.3%) patients remained free from
disability progression with ﬁngolimod treatment.
When patients were stratiﬁed according to four EDSS
categories, i.e. <1, 1 to <4, 4 to <7 and 7 to <8 as
deﬁned in [13], 214 (78.1%) patients belonged to the
category ‘1 to < 4’ (i.e. minimal to moderate disability
[13]) at ﬁngolimod initiation. Under ﬁngolimod treat-
ment, 257 (94.4%) patients remained in the same or
moved to a lower grade disability category (Fig. 3a).
Table 1 Patient characteristics
Patients (n) 274
Age (years)
Mean (SD) 39.9 (9.5)
Median (min.–max.) 40.0 (19–69)
Gender [n (%)]
Male 95 (34.7%)
Female 179 (65.3%)
RRMS disease duration (years)
Mean (SD) 6.3  6.4
Median (min.–max.) 4.2 (0.0–30.2)
RRMS treatment status at start of ﬁngolimod [n (%)]
Treatment na€ıve (ﬁrst-line) 78 (28.5%)
Pre-treated (switch) 196 (71.5%)
Fingolimod treatment duration (months)
Mean (SD) 32.0  11.8
Median (min.–max.) 31.1 (7.0–57.9)
EDSS at start of ﬁngolimod
Mean (SD) 2.4  1.3
Median (min.–max.) 2.0 (0.0–7.5)
EDSS, Expanded Disability Status Score; RRMS, relapsing-remit-
ting multiple sclerosis.
Figure 1 Patients’ pre-treatment history showing the disease-
modifying therapy given before the switch to ﬁngolimod. ,
interferons; , natalizumab; , glatiramer acetate; , other
treatment; , no pre-treatment.
Figure 2 Proportion of patients free from relapse under ﬁn-
golimod for the total analysis set and for subgroups according
to treatment history, i.e. treatment na€ıve and pre-treated. Pre-
treated patients were further stratiﬁed according to their last
multiple sclerosis therapy prior to switch to ﬁngolimod: natal-
izumab or injectable disease-modifying therapy (i.e. interferons
or glatiramer acetate). The number of patients for each sub-
group is shown at the bottom of each bar.
Table 2 Number of relapses under ﬁngolimod by treatment duration
Fingolimod
treatment
duration
No. of relapses under ﬁngolimod
TotalNone 1 2 3
n % n % n % n % n %
<1 year 11 91.7 1 8.3 0 0.0 0 0.0 12 100.0
1 to <2 years 52 82.5 8 12.7 2 3.2 1 1.6 63 100.0
2 to <3 years 70 76.9 15 16.5 5 5.5 1 1.1 91 100.0
≥3 years 80 74.1 20 18.5 6 5.6 2 1.9 108 100.0
© 2018 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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At ﬁngolimod start, the median EDSS (interquartile
range) of the total population was 2.0 (1.5–3.0). At
the last available follow-up, EDSS was 2.0 (1.0–3.0)
(P = 0.001).
Na€ıve patients prescribed with ﬁngolimod as a ﬁrst-
line therapy showed a signiﬁcant reduction of median
EDSS [from 2.0 (2.0–2.5) to 1.5 (0.0–2.5), P < 0.001),
whereas pre-treated patients who were switched to ﬁn-
golimod showed stable EDSS values [2.0 (1.5–3.5) and
2.0 (1.5–3.0), respectively, P = 0.659] at these two time
points (Fig. 3b). A total of 194 (72.1%) patients were
free from any clinical disease activity.
Fingolimod retention
A total of 262 (95.6%) and 199 (72.6%) patients were
treated with ﬁngolimod for more than 12 and
24 months, respectively. The treatment retention rates
over diﬀerent treatment periods are displayed in Fig. 4.
At the time of data documentation, 29 patients (10.6%)
had discontinued ﬁngolimod use. Reasons for discon-
tinuation were lack of efficacy in 11 (4.0%) patients and
adverse events in 11 (4.0%) patients, including viral
infections (e.g. herpes zoster and human papilloma
virus, all rated as ‘non-serious’ by the respective physi-
cian) in ﬁve patients and basal cell carcinoma in two
patients; nausea, cholecystitis and lymphoid papulosis
were reported as discontinuation reasons for one
patient each. Two patients discontinued ﬁngolimod due
to pregnancy, three due to a planned pregnancy and
ﬁve due to further undeﬁned patient decision. No car-
diovascular adverse events were reported by the physi-
cians as reasons for ﬁngolimod discontinuation.
Discussion
The important role of data obtained from real-world
observational studies in complementing evidence from
clinical trials is increasingly acknowledged. Speciﬁcally
in the ﬁeld of multiple sclerosis, a recent publication
endorsed the beneﬁts of using data from multiple
study types and data sources [14], particularly includ-
ing patient cohorts that would not be classically
Figure 3 (a) Transition between pre-deﬁned Expanded Disability
Status Score (EDSS) categories (<1, 1 to <4, 4 to < 7 or 7 to
<8). Rate of patients without change ( ) and with a transition
to a lower ( ) or higher ( ) disability category. (b) Median
EDSS before and under ﬁngolimod therapy, stratiﬁed according
to treatment history. For treatment-na€ıve patients ( ), a signiﬁ-
cant improvement of EDSS was seen (P < 0.001), whereas for
pre-treated patients ( ), EDSS remained stable under ﬁn-
golimod. Box plots represent median EDSS, interquartile range
(box margins) and minimum and maximum range (whiskers).
Figure 4 Fingolimod treatment retention, i.e. the proportion of
patients who, at a given time point, had retained ﬁngolimod treat-
ment. The number at the bottom of each bar represents the num-
ber of patients available for the respective period and the number
at the top of each bar represents the percentage of patients who
were still receiving ﬁngolimod treatment at that time.
© 2018 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
LONG-TERM FINGOLIMOD USE UNDER REAL-LIFE CONDITIONS IN SWITZERLAND 765
eligible for randomized clinical trials, and thus, reﬂect-
ing a real-world patient population.
Over 90% of our study population, including Swiss
patients with RRMS treated with ﬁngolimod under
real-life conditions, remained free from relapses over a
median treatment period of 31 months. The proportion
of patients free from relapses was similar when stratify-
ing patients according to ﬁrst-line (na€ıve patients) or
second-line indication, independent of the treatments
received before ﬁngolimod start. It is of note that these
results are conﬁrmed even for natalizumab treatment,
which is known to be associated with a potential risk of
disease activity rebound in the months following its dis-
continuation [15,16]. Interestingly, we did not observe
this phenomenon. The majority of patients switching
from natalizumab had been discontinued within
3 months prior to ﬁngolimod start. Thus, it is also unli-
kely that the low relapse rate observed in this subgroup
represents a regression to the mean eﬀect after relapses
occurred during the wash-out period after natalizumab
discontinuation.
The majority of patients also achieved a long-term
stabilization of EDSS, supporting the ﬁndings from
clinical trials and other long-term observational clinical
studies [5,6,8]. In addition, treatment-na€ıve patients
showed a signiﬁcant improvement of their EDSS, prob-
ably reﬂecting a recovery from the relapse that moti-
vated ﬁngolimod start and the larger compensatory
capacity known to characterize younger patients
[17,18]. At ﬁrst glance, the size of this eﬀect may appear
too small to be of clinical relevance [13]. It should be
noted, however, that the majority of treatment-na€ıve
patients presented a priori with low EDSS. Thus, the
attenuation of disability progression observed here in
very early stages of the disease, even if small, might rep-
resent a particular beneﬁt for these patients – a ﬁnding
well in line with current treatment guidance stipulating
an early initiation of eﬀective DMT to achieve better
long-term outcomes in patients with RRMS [1,2].
The rate of patients who were treated with ﬁn-
golimod as a ﬁrst-line therapy in our sample was
28.5%. In another Swiss study that was performed
within only 1 year of the Swiss market launch of ﬁn-
golimod, the proportion of treatment-na€ıve patients
was approximately 12% [19]. It seems plausible that
adoption of ﬁngolimod use depends not only on the
physicians’ familiarity with the drug, but also on the
availability of real-life data supporting eﬀectiveness
and a good tolerability proﬁle.
Treatment retention, satisfaction, tolerability and
adherence are prerequisites for treatment eﬀectiveness
and long-term therapeutic success [3]. In comparison
to other real-world studies, the mean treatment dura-
tion of 32 months in our study is relatively long, and
the retention rates, e.g. 95.7% at 24 months and
87.8% at 36 months, are mostly higher than previ-
ously reported treatment retention rates for ﬁn-
golimod under real-life conditions (reviewed by
Ziemssen et al. [8]). For instance, in other real-world
studies, Alroughani et al. [10] showed a ﬁngolimod
discontinuation rate of 5.3% after a mean treatment
duration of 18.5 months, whereas Yamout et al. saw
a discontinuation rate of 28.7% after a mean treat-
ment duration of 19.2 months [9]. Indeed, in our
study, only patients receiving continuous ﬁngolimod
treatment for at least 6 months were included, which
might have led to a selection bias towards patients
who were more likely to continue ﬁngolimod in the
long term. Nonetheless, we believe that the high reten-
tion rates at 24 and 36 months observed in our sam-
ple suggest a good long-term acceptance of and
satisfaction with ﬁngolimod treatment under
real-life conditions. Adverse events and/or lack of
efficacy were given as the most frequent reasons for
discontinuation.
Real-world evidence studies like ours have inherent
limitations. Firstly, we have no magnetic resonance
imaging data supporting our clinical results. Available
data on magnetic resonance imaging lesion load were
indeed collected but, in the course of evaluation, it
became apparent that the time windows deﬁned in the
observational plan were often violated and important
data were incompletely documented. Thus, these data
were not analyzed in detail. Second, the observational
(i.e. uncontrolled) and retrospective study design
exposes the study to the risk of selection and report-
ing bias, which cannot be ruled out entirely.
Finally, due to the study design, safety data were
collected only upon drug discontinuation, these
remaining, however, within the known safety proﬁle
of ﬁngolimod. Despite these limitations, the popula-
tion in the present study represents approximately 5%
of the entire patient population with RRMS in
Switzerland receiving a DMT [20]. The data obtained
in this population therefore probably reﬂect the cur-
rent use of ﬁngolimod in Swiss patients with RRMS.
Moreover, our results are of interest not only for
Switzerland, where ﬁngolimod is also approved as a
ﬁrst-line multiple sclerosis therapy, but also for other
countries such as the USA and Australia sharing simi-
lar indications.
In conclusion, our data show that under ﬁrst- as
well as second-line real-life use of ﬁngolimod:
(i) a high proportion of patients with RRMS achieve
or maintain relapse freedom and/or freedom from
disability progression over a mean follow-up of
32 months, irrespective of previous treatment
history and
© 2018 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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(ii) over this time interval, ﬁngolimod is continued
by the majority of patients.
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